Your browser doesn't support javascript.
loading
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
Stroes, Charlotte I; Schokker, Sandor; Creemers, Aafke; Molenaar, Remco J; Hulshof, Maarten C C M; van der Woude, Stephanie O; Bennink, Roel J; Mathôt, Ron A A; Krishnadath, Kausilia K; Punt, Cornelis J A; Verhoeven, Rob H A; van Oijen, Martijn G H; Creemers, Geert-Jan; Nieuwenhuijzen, Grard A P; van der Sangen, Maurice J C; Beerepoot, Laurens V; Heisterkamp, Joos; Los, Maartje; Slingerland, Marije; Cats, Annemieke; Hospers, Geke A P; Bijlsma, Maarten F; van Berge Henegouwen, Mark I; Meijer, Sybren L; van Laarhoven, Hanneke W M.
Afiliação
  • Stroes CI; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Schokker S; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Creemers A; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Molenaar RJ; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Hulshof MCCM; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • van der Woude SO; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Bennink RJ; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Mathôt RAA; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Krishnadath KK; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Punt CJA; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Verhoeven RHA; Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
  • van Oijen MGH; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Creemers GJ; Catharina Hospital, Eindhoven, the Netherlands.
  • Nieuwenhuijzen GAP; Catharina Hospital, Eindhoven, the Netherlands.
  • van der Sangen MJC; Catharina Hospital, Eindhoven, the Netherlands.
  • Beerepoot LV; Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.
  • Heisterkamp J; Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.
  • Los M; Sint Antonius Hospital, Nieuwegein, the Netherlands.
  • Slingerland M; Leiden University Medical Center, Leiden, the Netherlands.
  • Cats A; Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hospers GAP; University Medical Center Groningen, Groningen, the Netherlands.
  • Bijlsma MF; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • van Berge Henegouwen MI; Oncode Institute, Amsterdam, the Netherlands.
  • Meijer SL; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • van Laarhoven HWM; Amsterdam University Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
J Clin Oncol ; 38(5): 462-471, 2020 02 10.
Article em En | MEDLINE | ID: mdl-31809243
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article